FundedIQ
Biotechnology

Perfuze

Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland. The founders have over 30 years combined medtech experience within start-up and large corporations.Perfuze is developing innovative medical technology to treat acute ischemic stroke.Perfuze is developing innovative catheter technology to treat acute ischemic stroke. Their technology is intended to provide superior clinical outcomes in shorter procedural times; resulting in safe, cost-effective therapy. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. The founders have over 30 years combined medtech experience within start-up and large corporations. Perfuze is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway.

www.perfuze.com Newcastle, Ireland 11-50 employees
Total raised
$49.6M
Latest round: +93% of prior total
Rounds
2
Latest
Series Unknown
Mar 2025

Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland. The founders have over 30 years combined medtech experience within start-up and large corporations.Perfuze is developing innovative medical technology to treat acute ischemic stroke.Perfuze is developing innovative catheter technology to treat acute ischemic stroke. Their technology is intended to provide superior clinical outcomes in shorter procedural times; resulting in safe, cost-effective therapy. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. The founders have over 30 years combined medtech experience within start-up and large corporations. Perfuze is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway.

Perfuze has raised $49.6M across 2 rounds. Its most recent round was a Series Unknown of $23.9M in Mar 2025. Full funding history, investors, and team are detailed below.

Funding history

2 rounds · 1 visible Unlock with plan

2 rounds on record — latest round shown, the rest unlock with a paid plan.

Date
Round
Amount
Lead investor
Mar 13, 2025
Series Unknown
$23.9M

Unlock 1 earlier round — dates, amounts, round types — plus the lead investor for every round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

Perfuze is featured in

Similar companies

Luminate Medical

Luminate Medical develops a medical device designed to prevent hair loss during chemotherapy. Luminate Medical recognises that hair is an essential element of personality and self-esteem, and is dedicated to using the latest advances in medical technology to protect this.

Venture - Series Unknown $17.0M
Antler Bio

Antler Bio employs gene expression data to assist in herd management and provides services for analyzing genomic data.

Seed $4.3M
Nemysis

Nemysis unique strategy is a staged approach to the development of OTC and Prescription Products, tackling the same conditions to commercialise in different market segments. Nemysis is developing Food Supplements, Medical Matrix and Prescription products based on this strategy.

Series Unknown
Neuromod Devices

Neuromod is a medical device company formed to advance the science of bi-modal neuromodulation. We are committed to delivering treatments that significantly reduce the suffering of underserved patient populations who live with chronic and debilitating conditions globally. Our goal is to design products that empower patients to take control of their own treatment, delivering targeted therapies that integrate seamlessly into a modern lifestyle. Neuromod has developed and patented a bi-modal neuromodulation technology that it is evaluating for neurological disorders including chronic tinnitus, a condition affecting 10% of the adult population and commonly known as 'ringing in the ears'.

Series B $10.9M
Relevium Medical

Relevium Medical is a biopharmaceutical company with offices in both Ireland and the US that aims to enhance the quality of life for individuals suffering from chronic pain disorders by developing advanced treatments.

Series Unknown $4.8M
Ovagen

Ovagen Group Limited is a veterinary company based out of Ballina, Mayo, Ireland.

Series A $2.2M
SOMAÍ Pharmaceuticals

SOMAÍ is committed to building a strong global brand offering innovative cannabis-based therapeutics, aimed at promoting healthy lifestyles through natural medicine. Our focus is on developing a diverse range of cannabis products for chronic conditions, with a goal of providing a seamless experience for patients in administering and purchasing their medication. Operating in Lisbon, Portugal, SOMAÍ Pharmaceuticals is a European biotech company that adheres to EU-GMP standards, ensuring the consistent and effective delivery of cannabinoid pharmaceuticals worldwide. Our emphasis on scientific research and pharmacology allows us to cater to the endocannabinoid system in all markets.

Series B $4.3M
Beyondbmi

Beyondbmi offers specialized doctors and nutritionists who focus on managing weight, as well as the most up-to-date medications for weight loss. They also provide health coaches who offer support, motivation, and accountability. Their goal is to provide compassionate medical knowledge and the most current treatments to improve the lives of individuals with obesity.

Seed $1.1M
Amara Therapeutics

Amara Therapeutics is passionate about empowering women and men to take control of their pelvic health. Amara Therapeutics use evidence based medicine and behavioural interventions supported by Amara Therapeutics platform of technologies to provide safe, convenient and non-invasive care pathways. At Amara Therapeutics mission is to fix the care pathway for pelvic health patients, connecting healthcare providers, patients and peers through our platform.

Seed $1.6M
Vivasure Medical

Medical device company developing a closure device for vascular access procedures.

Series D $32.2M
Carrick Therapeutics

Carrick Therapeutics is pioneering a portfolio of unique, first in class, cancer treatments that target driver mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient’s tumour. Targeting the molecular pathways that drive the most aggressive and resistant forms of cancer will transform the way that cancer is treated and have a major impact on the lives of cancer patients. By linking a network of clinicians and scientists in internationally leading research institutes and hospitals, Carrick will streamline the introduction of these ground-breaking cancer therapies into the clinic, thus serving cancer patients around the world.

Series Unknown $35.0M
Impedans

Impedans furnish you with astute detecting stages for radio-recurrence (RF) and plasma process checking. Their items find applications in central exploration, process advancement, device configuration, process control and issue identification and order (FDC). They serve a large number of ventures, because of the omnipresent idea of RF and plasma handling, for example, semiconductor, vacuum covering, clinical gadget, hard circle and aviation among numerous others. Their offer is that They give you an autonomous finding of your cycle wellbeing, utilizing wise, web empowered detecting stages, related to their tremendous involvement with RF and plasma frameworks, to assist you with settling the most perplexing handling issues.

Series B $3.6M
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.